CymaBay Therapeutics, Inc. Company Review & Valuation

CBAY
Nasdaq
Latest Price
3.15USD
Market Capitalization
266.71mUSD

About CymaBay Therapeutics, Inc.

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.

Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.

The company also develops arhalofenate, which has completed five Phase II clinical trials for the treatment of patients with gout; and MBX-2982, an oral G-protein coupled receptor agonist that has completed one Phase II clinical trial for therapeutic indications.

It has licensing agreement with Kowa Pharmaceuticals America, Inc.

for the development and commercialization of arhalofenate in the United States; and Janssen Pharmaceuticals, Inc.

to develop and discover undisclosed metabolic disease target agonists for the treatment of type II diabetes and other disorders, as well as a license and development agreement with DiaTex, Inc.

to develop and commercialize therapeutic products comrprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases.

The company was formerly known as Metabolex, Inc.

CymaBay Therapeutics, Inc.

was incorporated in 1988 and is headquartered in Newark, California.

Industry
Biotechnology
HQ Location
Newark, California

Stock Price

Price data not available for CymaBay Therapeutics, Inc..

Performance

Please login or create a free account to view the contents of this section.

Financial Reports

Please login or create a free account to view the contents of this section.

Similar Companies

back to top

Valuu.io

Valuu provides insights and tools for self-directed stock investors. It enables you to easily find, valuate and track your stock investments with the help of reliable financial data and transparent analysis tools.

Disclaimer: This website is a data portal, which aggregates information about public companies. It is not a stock broker and does not give advice concerning specific investment decisions or tax or legal advice. All data is provided "as-is" with no guarantee for correctness and/or completeness. All company names, logos, and brands are intellectual property of their respective owners. The use of them is for editorial purposes only and does not imply any affiliation or endorsement.
© 2019-2022 Valuu Analytics Sàrl